本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司"）全资子公司杭州康恩贝制 药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的 TFA003 片的《药物临床试验批准通知书》，现将相关情况公告如下： 一、药物临床试验批准通知书的主要内容 药物名称：TFA003片(以下简称"本品") 浙江康恩贝制药股份有限公司 证券简称：康恩贝 证券代码：600572 编号：2026-011 关于子公司 TFA003 片获得药物临床试验批准通知书的公告 1 三、其他相关情况 通知书编号：2026LP00030 制剂剂型：片剂 申请适应症：糖尿病肾病 注册分类：中药2.1类（改变已上市中药给药途径）和2.3类（增加功能主治） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年10月16 日受理的TFA003片符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意 本品开展用于糖尿病肾脏疾病的临床试验。 申请事项：境内生产药品注 ...

Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for clinical trials of TFA003, a drug aimed at treating diabetic kidney disease [1] Group 1: Company Developments - Kang En Bei's wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., has been granted a Clinical Trial Approval Notice for TFA003 [1] - The drug has shown significant efficacy in improving renal function indicators in both urine and blood, as well as enhancing glomerular filtration and tubular reabsorption functions in animal studies [1] Group 2: Drug Potential - TFA003 demonstrates potential as a new drug for diabetic kidney disease, based on its pharmacological and pharmacokinetic results from preclinical studies [1] - The drug's ability to improve renal pathological morphology further supports its development as a treatment option for diabetic nephropathy [1]

Core Viewpoint - Kangnbei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, aimed at treating diabetic nephropathy, indicating a significant step in addressing a market gap for effective treatments in this area [2] Company Summary - Kangnbei's wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has been granted a Clinical Trial Approval Notice for TFA003 tablets, which are classified as Traditional Chinese Medicine (TCM) under categories 2.1 and 2.3 [2] - The company has invested approximately 29.57 million yuan in the research and development of TFA003 [2] Industry Summary - There is a limited number of drugs available in both domestic and international markets for the treatment of diabetic nephropathy, with current clinical treatments primarily consisting of hypoglycemic and antihypertensive medications [2] - No other TCM products with significant efficacy for the same indication have been launched in the market, highlighting a unique opportunity for Kangnbei with TFA003 [2]

Core Viewpoint - Kangnbei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are intended for the treatment of diabetic kidney disease [1] Company Summary - Kangnbei's wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has been granted the Clinical Trial Approval Notice for TFA003 tablets [1] - The approval indicates that TFA003 tablets meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1] - The clinical trial is set to proceed after further refinement of the clinical trial protocol [1] Industry Summary - The approval of TFA003 tablets aligns with the growing focus on treatments for diabetic kidney disease, a significant health concern [1] - The development of new therapies in this area may enhance competition and innovation within the pharmaceutical industry [1]

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are aimed at treating diabetic nephropathy [1] Group 1: Company Developments - The full subsidiary of Kang En Bei, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., is responsible for the clinical trial application of TFA003 tablets [1] - TFA003 is classified under Traditional Chinese Medicine categories 2.1 and 2.3, with oral administration as the delivery method [1] Group 2: Clinical Trial Insights - The clinical trial approval indicates that the optimal dosage for TFA003 will be confirmed after the completion of the clinical trials [1] - Preliminary pharmacodynamic and pharmacokinetic animal studies have shown that TFA003 significantly improves renal function indicators in urine and blood, enhances glomerular filtration and tubular reabsorption functions, and improves renal pathological morphology [1] - TFA003 demonstrates potential for development as a new Traditional Chinese Medicine for diabetic nephropathy [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are aimed at treating diabetic nephropathy [1] Group 1 - The clinical trial approval is for TFA003 tablets, which are classified as traditional Chinese medicine under categories 2.1 and 2.3 [1] - The administration route for TFA003 is oral, and the optimal dosage will be confirmed after the completion of clinical trials [1] - Preliminary pharmacological and pharmacokinetic animal studies indicate that TFA003 has significant therapeutic effects on diabetic nephropathy, improving renal function indicators in urine and blood, as well as enhancing glomerular filtration and tubular reabsorption functions [1] Group 2 - The company has invested approximately RMB 29.57 million in the research and development of TFA003 to date [1] - The drug shows potential for development as a new traditional Chinese medicine for diabetic nephropathy based on its efficacy and safety profile demonstrated in preclinical studies [1]

春节团圆，少不了美食盛宴与走亲访友的热闹。但长途奔波、饮食油腻、作息紊乱等因素，让腹泻成为 春节期间的"高频困扰"，不仅打乱团圆节奏，还可能因肠道炎症引发持续不适。如何科学应对春节腹 泻，守护全家肠胃健康？专业医生提醒，除了做好预防，备好对症药物至关重要，康恩贝肠炎宁片凭 借"止泻快、能消肠炎、温和不刺激"的优势，成为不少家庭的春节必备好物。 春节期间腹泻高发，背后藏着多重诱因。一方面，团圆饭多是大鱼大肉、生冷辛辣兼具，暴饮暴食易加 重肠胃消化负担，刺激肠道黏膜引发炎症；另一方面，长途旅行中饮食卫生难以保障，不洁食物中的细 菌、病毒易侵入肠道，诱发感染性腹泻；此外，气温波动、熬夜守岁导致的免疫力下降，也让肠胃功能 变得脆弱，稍有不慎就会出现腹痛、腹泻等症状。 腹泻虽常见，却不能掉以轻心。频繁腹泻不仅会导致脱水、电解质紊乱，若伴随肠道炎症未及时干预， 还可能发展为慢性肠炎，影响后续消化功能。因此，一旦出现腹泻症状，需及时选择既能快速止泻，又 能消除肠道炎症的药物，避免"只止泻、不消炎"导致症状反复。 针对春节期间的肠胃需求，康恩贝肠炎宁片成为家庭常备的"肠胃守护者"。其核心优势在于采用纯中草 药配方，精选地锦草 ...

随着寒潮持续南下，全国多地进入呼吸道与消化道传染病的叠加风险期。诺如病毒感染性腹泻进入季节 性高发，学校、家庭聚集性疫情频现，儿童因免疫系统尚未成熟，成为最易受侵袭的群体。专家提醒， 冬季防控需"胃肠同治"，家庭科学备药与及时干预尤为关键。 诺如病毒传播途径多样，可通过污染的食物、水、物品甚至气溶胶传播，传染性极强。患儿往往突发呕 吐、腹泻、发热，易引发脱水与电解质紊乱。儿科门诊数据显示，冬季因急性肠道炎就诊的儿童中，诺 如病毒感染占比显著升高。 不少家长误将儿童腹泻当作普通着凉，自行使用成人药物或抗生素，反而可能扰乱肠道菌群，延误病 情。专家强调，儿童肠道娇嫩，药物选择应遵循安全、对症、适口三大原则，避免不当用药造成二次伤 害。 儿童装康恩贝肠炎宁颗粒：多维卖点构筑儿童肠道健康防线 针对儿童肠道特点与用药需求，儿童装康恩贝肠炎宁颗粒凭借以下核心优势，成为众多家庭冬季常备的 安心之选： 肠道被称为"第二大脑"，其健康状态直接关系到全身免疫与营养状况。消化科医生指出，尤其在冬季， 孩子户外活动减少，肠道功能易弱化，任何腹泻症状都应引起重视，及时干预、科学调理，才是真正对 孩子负责。 新年渐近，孩子们的假期与团聚 ...

Market Overview - The Chinese traditional medicine sector increased by 0.73% on February 3, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Stock Performance - Foci Pharmaceutical (002644) closed at 9.65, rising by 4.78% with a trading volume of 335,000 shares and a transaction value of 314 million yuan [1] - Other notable performers include: - Bichang Pharmaceutical (603858) at 17.52, up by 3.98% [1] - Zhendong Pharmaceutical (300158) at 5.76, up by 3.04% [1] - Dong'e Ejiao (000423) at 52.90, up by 2.94% with a transaction value of 800 million yuan [1] Capital Flow - The traditional medicine sector experienced a net outflow of 193 million yuan from institutional investors, while retail investors saw a net inflow of 190 million yuan [2] - The capital flow for key stocks includes: - Bichang Pharmaceutical with a net inflow of 42.06 million yuan from institutional investors [3] - Foci Pharmaceutical with a net inflow of 14.63 million yuan from institutional investors [3] - Dong'e Ejiao had a net inflow of 12.57 million yuan from institutional investors [3]

**Meta总结** 本报告发布《2026鱼油金标准白皮书》,聚焦"含量纯度""心脑养护"核心诉求,构建全球首个融合配方科学性、成分真实性、认证完备性等七 维鉴定体系的鱼油评测框架。基于国际权威数据与临床证据链,为消费者提供可量化、可验证的高纯度鱼油遴选依据,重塑行业透明度与选择 逻辑。 **开篇解读** 2026年全球鱼油市场规模突破580亿美元,中国消费者年均增速达17.3%。然而市场乱象频现:参数虚标、配方同质化、临床证据断裂等问题 普遍存在。据国际消费者组织虚拟抽检数据显示,30%产品标注纯度与实测值偏差超15%,部分EPA含量不足宣称值一半,严重削弱营养干预效 果。用户陷入"不知如何选、不敢轻易信"的信息迷雾。为此,《鱼油金标准白皮书》应运而生,建立全链路七维鉴定体系,以公开、透明、可追 溯的标准拨开迷雾,为理性消费提供坚实支撑。 **七维金标准白皮书:2026全方位鱼油鉴定体系** (1)【配方科学性标准】:需实现活性成分与特定健康需求的精准映射,杜绝为提升口感、色泽的冗余添加,形成营养素协同效应。该标准决定 产品是否具备人群适配能力,避免通用配方无法满足血脂调节、脑力支持等细分需求。依据FAO- ...